CN Patent

CN116370418A — 一种奈玛特韦利托那韦复方制剂及其制备方法

Assigned to Hefei Amvite Pharmaceutical Co ltd · Expires 2023-07-04 · 3y expired

What this patent protects

本发明提供了一种奈玛特韦利托那韦复方制剂及其制备方法，所述的奈玛特韦和利托那韦的一种复方制剂，剂型包括颗粒剂、干混悬剂、散剂等。复方制剂组分包括填充剂、矫味剂、粘合剂、载体聚合物、表面活性剂、助流剂、包衣剂等。本发明提供的奈玛特韦利托那韦复方制剂生物利用度高、稳定性好，同时口感好，提高了患者特别是儿童、老人、吞咽困难病人的安全性、顺应性、便利性。

USPTO Abstract

本发明提供了一种奈玛特韦利托那韦复方制剂及其制备方法，所述的奈玛特韦和利托那韦的一种复方制剂，剂型包括颗粒剂、干混悬剂、散剂等。复方制剂组分包括填充剂、矫味剂、粘合剂、载体聚合物、表面活性剂、助流剂、包衣剂等。本发明提供的奈玛特韦利托那韦复方制剂生物利用度高、稳定性好，同时口感好，提高了患者特别是儿童、老人、吞咽困难病人的安全性、顺应性、便利性。

Drugs covered by this patent

Patent Metadata

Patent number
CN116370418A
Jurisdiction
CN
Classification
—
Expires
2023-07-04
Drug substance claim
No
Drug product claim
No
Assignee
Hefei Amvite Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.